Biotechnology Industry | Healthcare Sector | Mr. Christian Kanstrup M.Sc. CEO | NASDAQ (CM) Exchange | US29970R1059 ISIN |
US Country | 49 Employees | - Last Dividend | 22 Jan 2024 Last Split | 5 Feb 2021 IPO Date |
Evaxion Biotech A/S represents a forefront clinical-stage biotech entity distinguished by its specialized focus on the development of immunotherapies powered by artificial intelligence. Incorporated in 2008 and having its foundations in Horsholm, Denmark, the company is pioneering in the research and development of novel treatments targeting a range of cancers and infectious diseases. By leveraging the potential of AI, Evaxion Biotech A/S aims to enhance the precision and effectiveness of immunotherapies, paving the way for significant advancements in medical treatments.
Evaxion Biotech A/S boasts an extensive portfolio concentrated on immunotherapies and vaccines, each at varying stages of clinical and pre-clinical development. The following outlines their primary products and services: